NEW YORK (GenomeWeb News) – Saladax today announced a deal with InyDia Labs for the distribution of the My5-FU test in Spain and Portugal.
Saladax's My5-FU test measures levels of the oncology drug 5-fluorouracil, or 5-FU, in the blood of cancer patients, and the deal with InyDia makes it the exclusive provider of My5-FU test kits in the two countries.
Financial terms of the deal were not disclosed.
Based in Madrid, InyDia specializes in the production of in vitro diagnostic reagents and instruments, such as array readers and liquid handling platforms. It also offers personalized medicine products from other manufacturers.
Saladax is based in Bethlehem, Penn., and last month said it was partnering with the Central European Society for Anticancer Drug Research to study metastatic colorectal cancer patients treated with 5-FU using the My5-FU technology. The company also announced a distribution deal for the test covering Poland and Italy in December.